<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04316871</url>
  </required_header>
  <id_info>
    <org_study_id>EPMDose</org_study_id>
    <nct_id>NCT04316871</nct_id>
  </id_info>
  <brief_title>Dosage of Epidural Morphine in Elderly Patients</brief_title>
  <official_title>Epidural Morphine for Elderly Patients Undergoing Lower Abdominal Cancer Surgery: a Dose Response Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This a clinical trial that evaluates the efficacy and safety of three different doses of&#xD;
      morphine, namely 1.5 mg, 3 mg and 4.5 mg, via the epidural route regarding reducing pain in&#xD;
      elderly patients after a cancer surgery in the lower abdomen&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acute postoperative pain is a common complaint for several days after surgery. However, acute&#xD;
      postoperative pain remains even more under controlled in elderly patients, especially those&#xD;
      with cognitive impairment and malignancy. Geriatric population is reported to be at higher&#xD;
      risk for unwanted side effects from analgesic treatments compared to younger patients due to&#xD;
      different major risk factors such as: decline in organ function, polypharmacy,&#xD;
      pharmacokinetics, drug sensitivity, and frailty. Despite of the higher risk of opioids,&#xD;
      especially morphine, causing toxicity and adverse effect; they are still the cornerstone&#xD;
      treatment of severe acute postoperative pain. Morphine in those patients is very likely to&#xD;
      cause toxicity because of accumulation of its active metabolites compared to other opioids&#xD;
      with fewer or no active metabolites. Epidural morphine is an effective route for an effective&#xD;
      drug. Furthermore, unwanted side effects with neuraxial opioids are minor and managed easily.&#xD;
      Regarding clinical outcomes, clinical studies showed a lot of improvements associated with&#xD;
      postoperative opioid analgesia. Now, there is a clinical necessity to achieve the best&#xD;
      management of acute postoperative pain in elderly patients with the least possibility of&#xD;
      adverse side effects. We aim in this randomized, assessor blinded, clinical trial at Assuit&#xD;
      University to determine the optimum dose of epidural morphine for the highest control of&#xD;
      acute postoperative pain in geriatrics who are planned to have lower abdominal cancer&#xD;
      surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 20, 2020</start_date>
  <completion_date type="Actual">June 30, 2021</completion_date>
  <primary_completion_date type="Actual">December 31, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total patient-controlled analgesia (PCA) morphine sulphate (MS) consumption.</measure>
    <time_frame>72 hours</time_frame>
    <description>It is an objective method to measure adequacy of pain control</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain-intensity measured using visual analog scale (VAS)</measure>
    <time_frame>72 hours</time_frame>
    <description>It is a subjective scale to assess pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ramsay sedation scale (RSS).</measure>
    <time_frame>72 hours</time_frame>
    <description>It is a subjective scale to assess drowsiness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nausea, vomiting and pruritis scale</measure>
    <time_frame>72 hours</time_frame>
    <description>It is a subjective scale to assess side effects of morphine</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">88</enrollment>
  <condition>Age Problem</condition>
  <condition>Abdominal Cancer</condition>
  <arm_group>
    <arm_group_label>Group D</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>where patients will receive epidural 15 ml of Marcaine 25% and and epinephrine 1:200,000.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>where patients will receive epidural 15 ml volume of 1.5 mg morphine sulphate (MS), Marcaine 25% and and epinephrine 1:200,000.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>where patients will receive epidural 15 ml volume of 3 mg morphine sulphate (MS), Marcaine 25% and and epinephrine 1:200,000.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>where patients will receive epidural 15 ml volume of 4.5 mg morphine sulphate (MS), Marcaine 25% and and epinephrine 1:200,000.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1.5 mg of Morphine Sulfate</intervention_name>
    <description>1.5 mg of Morphine Sulphate will be given epidurally.</description>
    <arm_group_label>Group A</arm_group_label>
    <other_name>A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>Normal saline will be given epidurally.</description>
    <arm_group_label>Group D</arm_group_label>
    <other_name>D</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>3 mg of Morphine Sulfate</intervention_name>
    <description>3 mg of Morphine Sulphate will be given epidurally.</description>
    <arm_group_label>Group B</arm_group_label>
    <other_name>B</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>4.5 mg of Morphine Sulfate</intervention_name>
    <description>4.5 mg of Morphine Sulphate will be given epidurally.</description>
    <arm_group_label>Group C</arm_group_label>
    <other_name>C</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        1. Men and women aged ≥ 60 years, who are planned to undergo lower abdominal cancer&#xD;
        surgery.&#xD;
&#xD;
        2- ASA I and II classifications. 2. Surgeries via infra-umbilical abdominal incision is&#xD;
        considered eligible.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient refusal.&#xD;
&#xD;
          2. Patients who are morbidly obese (body mass index ≥ 40 kg/m2).&#xD;
&#xD;
          3. Those with contraindications to neuraxial analgesia. 4- psychiatric illness that would&#xD;
             interfere with the perception and the assessment of pain.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Diab Hetta, MD</last_name>
    <role>Study Director</role>
    <affiliation>Assiut University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Assuit University</name>
      <address>
        <city>Assuit</city>
        <zip>71515</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>McKeown JL. Pain Management Issues for the Geriatric Surgical Patient. Anesthesiol Clin. 2015 Sep;33(3):563-76. doi: 10.1016/j.anclin.2015.05.010. Epub 2015 Jul 3. Review.</citation>
    <PMID>26315638</PMID>
  </reference>
  <reference>
    <citation>Palmer CM, Nogami WM, Van Maren G, Alves DM. Postcesarean epidural morphine: a dose-response study. Anesth Analg. 2000 Apr;90(4):887-91.</citation>
    <PMID>10735794</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 19, 2020</study_first_submitted>
  <study_first_submitted_qc>March 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 20, 2020</study_first_posted>
  <last_update_submitted>October 19, 2021</last_update_submitted>
  <last_update_submitted_qc>October 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Muhammad Mostafa Shawqi Abdelnasser</investigator_full_name>
    <investigator_title>Anesthesia resident at South Egypt Cancer Institute</investigator_title>
  </responsible_party>
  <keyword>Injections, Epidural</keyword>
  <keyword>Morphine Sulfate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abdominal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Morphine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

